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Abstract 
Surfactant protein C (SP-C) is an essential component for the surface tension-
lowering activity of the pulmonary surfactant system. It contains a valine-rich α 
helix that spans the lipid bilayer, and is one of the most hydrophobic proteins 
known so far. SP-C is also an essential component of various surfactant 
preparations of animal origin currently used to treat neonatal respiratory 
distress syndrome (NRDS) in preterm infants. The limited supply of this 
material, and the risk of transmission of infectious agents and immunological 
reactions have prompted the development of synthetic SP-C-derived peptides 
or recombinant humanized SP-C for inclusion in new preparations for 
therapeutic use. 
We describe herein the recombinant production in bacterial cultures of 
SP-C variants containing phenylalanines instead of the palmitoylated cysteines 
of the native protein, as fusions to the hydrophilic nuclease A (SN) from 
Staphylococcus aureus. The resulting chimerae were partially purified by affinity 
chromatography and subsequently subjected to protease digestion. The SP-C 
forms were recovered from the digestion mixtures by organic extraction and 
further purified by size exclusion chromatography. The two recombinant SP-C 
variants so obtained retained more than 50% α-helical content and showed 
surface activity comparable to the native protein, as measured by surface 
spreading of lipid/protein suspensions and from compression π-A isotherms of 
lipid/protein films. Compared to the protein purified from porcine lungs, the 
recombinant SP-C forms improved movement of phospholipid molecules into 
the interface (during adsorption), or out from the interfacial film (during 
compression), suggesting new possibilities to develop improved therapeutic 
preparations. 
Abbreviations 
DPPC: 1,2-dipalmitoyl phosphatidylcholine; LPC: lysophosphatidylcholine; LS: 
lung surfactant; NRDS: neonatal respiratory distress syndrome; POPG: 
palmitoyl oleyl phosphatidylglycerol; SDS-PAGE: sodium dodecylsulfate 
polyacryamide-gel electrophoresis; SP-C: surfactant protein C; rSP-C: 




Surfactant–associated protein C (SP-C) together with a second hydrophobic 
surfactant protein, SP-B, and phospholipids represents the active component of 
the lung surfactant (LS). LS is the surface active material present at the air-
liquid interface in the alveoli of mammalian lungs. Its role is to lower the 
normal air-water surface tension, from 70 mN/m to near zero, upon expiration, 
thereby preventing alveolar collapse and minimizing the work of their 
expansion during inhalation [1]. Deficiency or inactivation of LS causes 
pulmonary dysfunctions, the most common being neonatal respiratory distress 
syndrome (NRDS), caused by the absence of surfactant in premature infants. 
Replacement surfactants currently applied in clinical therapy are obtained from 
animal lungs. However, this is an expensive and inexact source, and levels of 
SP-B and SP-C in commercial surfactant preparations vary from batch to batch 
and are typically lower that in native pulmonary surfactants [2, 3]. 
Additionally, the potential risks of transmission of animal-derived diseases or 
immunological reaction justify the need for a human-like standardised material 
as a suitable alternative [4]. The possibility to optimise artificial surfactant 
formulations to treat specific diseases should also open new perspectives for the 
treatment of respiratory pathologies.  
Several efforts have been made in order to develop artificial mimics of 
the natural surfactant by combining synthetic lipids and peptides that 
correspond to segments of native SP-B and SP-C. Tests in vitro and in animal 
models show that their biophysical activity is usually superior to the one of 
phospholipids alone [5]. However, production of successful, entirely synthetic 
surfactant preparations has been so far hindered by the difficulties in obtaining 
both surfactant proteins, SP-B and SP-C, mainly due to their high 
hydrophobicity.  
SP-C, one of the most hydrophobic proteins in the proteome, is a 35 
amino acid polypeptide that constitutes approximately 1% of the surfactant 
mass [6]. It is composed of a short N-terminal region, palmitoylated at residues 
Cys-5 and Cys-6, and followed by an α-helical hydrophobic transmembrane 
(TM) C-terminal stretch made of aliphatic residues. The sequence of SP-C is 
highly conserved through evolution, with predominance of valine residues in 
the TM domain and only small differences between species (Fig. 1A). It is 
proposed that SP-C is involved in the formation of multilayer lipid stacks 
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attached to the air-liquid interface, which act as a source of reservoir of lipids 
that can be reinserted into the monolayer during alveolar expansion [7]. 
However, detailed molecular mechanistic studies are still missing.  
Apart from the above mentioned extreme hydrophobicity, the difficulty 
for obtaining artificial SP-C analogues derives from its strong tendency to 
misfold and aggregate in the absence of phospholipids [8, 9]. The TM α helical 
fragment, represented by 10-12 valines with intermittent Ile and Leu residues, is 
capable of populating irreversibly into a fibrilar β-structure aggregate. In 
aqueous solutions β-branched valines and isoleucines display a preference 
toward β-strands and are usually underrepresented in α helices. However, in 
lipid environments Val and Ile residues promote helix formation [10]. In 
agreement with this general tendency, the α helical polyVal-rich region of SP-C 
was found to convert spontaneously into β sheets in vitro, with an enhanced 
rate of α→β transition in the presence of polar solvents and deacylation [11]. 
Current data emphasize a strong correlation between the loss of helical 
structure of SP-C and its malfunctioning [12]. Moreover, SP-C amyloid fibrils 
are found in patients with pulmonary alveolar proteinosis [8]. 
The highly hydrophobic membrane proteins are generally difficult to 
over-express and purify [13]. They are usually produced in heterologous 
systems, as fusions with soluble portions of bacterial proteins. The presence of 
detergents during the purification is often required in order to prevent 
formation of aggregates, especially at the point where the TM portion is cleaved 
from its fusion. Following enzymatic cleavage the TM proteins are generally 
purified by reversed phase (RP) HPLC [14]. Membrane proteins that do not 
have fibril forming propensities can, once unfolded and precipitated, be 
recovered in the presence of detergents or lipids.  However, this three-step 
method is not readily applicable to SP-C, since purifying the protein by RP-
HPLC bears the risk of its denaturation leading to irreversible aggregation and 
complete inactivation. A method has been published for expression and 
purification of recombinant SP-C (rSPC) in Escherichia coli as a fusion to the N-
terminal portion of bacterial chloramphenicol acetyl transferase [15]. Surfactant 
preparations containing this version of rSP-C as the unique protein component 
have shown to be effective for the treatment of respiratory distress [16, 17]. 
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In this report, we describe a novel approach for expression and 
purification of human SP-C, based on the combination of a successful TM 
protein expression strategy in bacteria with the established organic extraction 
protocol typically used for separation of native SP-C from LS mixtures. This 
new procedure is very effective for preserving the native helical structure of SP-
C throughout the purification protocol and for producing protein forms with 
high surface activity in reasonable amounts. We have modified the SP-C 
sequence by Cys5Phe and Cys6Phe substitutions. The rationale behind these 
changes is that the naturally occurring palmitoylation of the two Cys residues 
cannot be achieved through bacterial protein expression. The modified protein 
remains very close to the native sequence present in some animal surfactants 
(Fig. 1). Moreover, the same Cys→Phe replacements are present in the SP-C 
analogue used in a successful synthetic surfactant preparation [18]. Detailed 
analysis of the highly pure rSP-C forms produced in this work reveals a slightly 
improved surface activity when compared to the native SP-C obtained from 
animal lungs. 
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 MATERIALS AND METHODS 
Protein expression and purification 
Construction of plasmids encoding the His-tagged chimerical protein 
(SN/GpA) has been described [19]. The glycophorin A (GpA) sequence in the 
original plasmid was replaced by a PCR-amplified sequence of human SP-C 
(generous gift from Dr. Joanna Floros, University of Pennsylvania at Hershey), 
using ApaI/BamHI restriction sites. The N-terminal His-tag, the optimised 
thrombin digestion site, and all point mutations in the wild type sequence of 
SP-C were introduced by site-directed mutagenesis using the QuikChange kit 
from Stratagene (La Jolla, California) and verified by DNA sequencing.  
The expression of the fusion protein was performed as described earlier 
[20]. Briefly, a 10 mL overnight culture of BL21 (DE3) pLys (Novagen, Madison, 
WI) cells transformed with the corresponding vector was inoculated into 1 L of 
LB medium and grown at 37 ºC until the OD600 reached 0.6. IPTG (1 mM) was 
added for induction and the culture was grown for additional 3 hours. The cells 
were harvested by centrifugation at 3800 g for 10 min in a Sorval centrifuge and 
resuspended in resuspension buffer (10 mM Tris HCl pH 7.9, 1 mM EDTA, 0.01 
M PMSF). Pellets were freezed until use. In order to break the cellular 
membranes, the pellets were freeze-thawed three times, sonicated and added to 
the same volume of TBS 1% lauroyl sarcosine detergent. This mixture was 
centrifuged at 18000 g for 10 minutes. The fusion protein was purified from the 
supernatant via immobilized metal affinity chromatography. An ÄKTA purifier 
liquid chromatography system (Amersham Bioscience) was used with a His-
Trap column filled with nickel containing resin. The buffers for chimerical 
protein purifications were the following: equilibration buffer, TBS 0.5% lauroyl 
sarcosine; wash buffer, TBS 0.2% lauroyl sarcosine 10mM imidazol; and elution 
buffer, TBS 0.2% lauroyl sarcosine 500 mM imidazol.  The eluted protein was 
dialysed to remove imidazol and finally concentrated by using an Amicon 
concentrator with YM10 ultra-filtration membrane (Milipore, Bedford MA) 5-6 





A thrombin cleavage site (LVPR↓GP), introduced between SN and SP-C, 
allowed the proteolysis of the fusion protein. A glycine-rich ‘kinker’ next to the 
thrombin cleavage site was introduced to improve the cleavage efficiency [21]. 
Thrombin (Novagen) digestion trials were performed before each large-scale 
digestion. Usually, 10 U of thrombin were required for digestion of 1 mg rSP-C 
and 1 U of thrombin was needed for 1 mg of rGP/SP-C.  Thrombin digestions 
were performed at 21 0C in the buffer recommended by the supplier, with 
shaking at 550rpm in eppendorf thermomixer. The reactions were concentrated 
again using a cell concentrator with membranes of 1 kDa molecular cut off. 
Aliquots taken from the digestion reaction mixture were applied to tris-tricine 
gels in order to monitor the appearance of the bands corresponding to the 
Staphylococcal nuclease (18.5 kDa) and rSP-C (3.9kDa) (Fig. 2B). 
 
Organic extraction 
An organic extraction of the protein solution was performed according to the 
protocol of Bligh and Dyer [22] for lipid extraction. Shortly, two volumes of 
methanol and one volume of chloroform were added to the protein mixture, 
which was vortexed and incubated at 370C. After addition of one more volume 
of chloroform and one of water, the mixture was vortexed and centrifuged at 
550 g/5min. The lower, organic, phase was collected and two volumes of 
chloroform were added two more times to the aqueous phase in order to 
increase protein recovery.  All organic phases were stored in glass bottles at -
200C.  The organic extract was concentrated to approximately 2 mL prior to 
application to the lipophilic column. Protein concentration was performed in 
the presence of egg yolk PC (Avanti Polar Lipids, Alabaster, AL) at a 1:5 (w:w) 
ratio in a rota-vaporizer apparatus. 
 
Sephadex LH-20 lipophilic size exclusion chromatography 
In order to eliminate components other than SP-C that could have co-purified in 
the organic phase, the organic extraction was applied to a Sephadex LH-20 
column (Amersham Biosciences). This column is used for lipid separation and 
is adapted to the use with organic solvents. Proteins and lipids are eluted from 
the column by a chlorofom:metanol (2:1, v:v) eluting system. Fractions were 
collected and absorbance at 240 and 280 nm was recorded on a 
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spectrophotometer.  Absorbance peaks were pooled and loaded on SDS-PAGE 




For determination of the molecular masses, 0.85 µL of the of peptide dissolved 
in chloroform:methanol (2:1, v:v) were spotted onto a MALDI-TOF sample 
holder and allowed to dry at room temperature. An equal volume of a 
saturated solution of sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) 
(Sigma) saturated in 70% acetonitrile containing 0.1% TFA was added, let dry, 
and analyzed with an Applied Biosystems Voyager-DE Pro MALDI-TOF mass 
spectrometer, operated in delayed extraction and linear or reflector modes. The 
mass calibration standard in linear mode consisted of a mixture of the following 
proteins, whose calculated isotope-averaged molecular masses in Daltons are 
given between brackets: bovine insulin (5734.6), E. coli thioredoxin (11674.5), 
horse apomyoglobin (16952.6). For reflector calibration, a tryptic peptide 
mixture of Cratylia floribunda seed lectin (SwissProt accession code P81517) 
prepared and previously characterised in our laboratory was used. 
 
Circular dichroism 
To prepare the samples for CD measurements, the purified protein (50 µg) in 
chloroform:methanol solutions was mixed with lysophosphatidylcholine (LPC) 
or DPPC:POPG (7:3) at a protein: lipid ratio of 1:5 (w:w), dried under a stream 
of N2 and then under vacuum for 2h. The resulting dried films were hydrated by 
addition of 0.5 mL of 5mM Tris buffer (pH 7) containing 150 mM NaCl with 
intermittent vortexing at room temperature for LPC micelles, or at 550C for 
DPPC:POPG vesicles. The suspensions were then sonicated during 1 min. CD 
spectra were obtained on a Jasco J-810 CD spectropolarimeter. Quartz cells of 1 
mm optical path were used to record spectra at a scanning speed of 50 nm/min. 
Generally, 15 scans were accumulated and averaged, subjected to noise 
reduction and corresponding blanks subtracted. Data analysis was performed 
with the help of the CDPro software package, which contains three commonly 
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used programs: SELCON3, CONTIN/LL and CDSSTR [23, 24]. This software 
allows the use of different reference sets of proteins, including 13 membrane 
proteins (SMP50), to increase the reliability of the analysis. 
 
SDS-PAGE 
Fusion proteins and protein samples obtained after organic extraction or eluted 
from the Sephadex column were analyzed onto 16% SDS-PAGE. The SP-C 
peptide samples were first evaporated under Nitrogen gas, resuspended in the 
loading buffer, boiled 5 min at 950C and applied to the gel. After running, gels 
were fixed, stained with Comassie blue stain and distained. In order to resolve 
small molecular mass peptides generated after thrombin digestion, the samples 
were loaded on tricine 15% acrylamide gel. Tricine gels were processed 
identically as SDS-PAGE gels. 
 
Interfacial adsorption 
Adsorption π-t kinetics for the formation of phospholipids films as promoted by 
native and recombinant forms of SP-C, were monitored on a Wilhemy surface 
balance (Nima, Coventry, UK) equipped with a minitrough (15 cm2 of surface, 5 
mL volume of sub-phase) and using a Whatman Nº 1 paper dipping plate 
attached to the pressure transducer. Hundred µg of a mixture of DPPC:POPG 
(7:3, w:w) containing 0, 2, 5 or 10% protein (w/w) were reconstituted in 100 µL 
of 5 mM Tris buffer pH 7.0 containing 150 mM NaCl. To start acquisition of the 
π-t adsorption isotherms, 10 µL of this suspension were deposited directly and 
allowed to spread on top of the surface of the balance and film formation was 
monitored following the changes in surface pressure with time. Experiments 
were performed at 25 ºC and repeated at least three times with two different 
samples for each protein. 
 
π-A compression isotherms 
Monolayers of lipid (DPPC:DPPG, 7:3, w/w) or lipid/peptide binary systems 
were made by spreading a small volume of a concentrated lipid or 
lipid/peptide solution in chloroform:methanol (3:1, v/v) at the surface of a 5 
mM Tris buffered sub-phase, pH 7, containing 150 mM NaCl.  These 
monolayers were prepared as previously described [25], in a thermostatic 
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(25°C) Langmuir-Blodgett trough (NIMA Technologies, Coventry, United 
Kingdom) equipped with a ribbon barrier to minimize film leakage during 
compression.  Sub-phases were prepared with double distilled water (the 
second distillation performed in the presence of potassium permanganate).  
After spreading the sample on top of the sub-phase, the organic solvent was 
allowed to evaporate for 10 minutes before starting compression. The total area 
of the interface was 225 cm2 and the monolayer was compressed at 65 cm2/min, 
while changes in surface pressure were recorded and plotted against the area 
occupied per phospholipid molecule. 
 11 
RESULTS 
Over-expression and digestion of chimeric proteins 
rSP-C is based on the primary sequence of human SP-C (Fig. 1). Two critical 
issues had to be considered to define the expression and purification strategy of 
this protein: the hydrophobicity conferred by the polyVal stretch and the 
palmitoylation at Cys-5 and Cys-6, which represents an insuperable challenge 
for the bacterial expression machinery. The high hydrophobicity was overcome 
by making a fusion with the hydrophilic nuclease A (SN) from Staphylococcus 
aureus (SN/SP-C, see Materials and Methods). An optimised thrombin cleavage 
site [21] is introduced between the SN and the SP-C sequence to allow removal 
of the nuclease moiety (Fig. 1C). In order to prevent possible dimer formation 
via disulphide bonds in the absence of palmitic chains we introduced a double 
C5C6→F5F6 mutation [26]. Phenylalanine residues were chosen because: i) they 
represent a native surrogate to the missing Cys-6 in the native SP-C of some 
animals (Fig.1A), ii) they have high propensity to partition into the membrane 
interface [27], and iii) the Cys→Phe substitutions were shown not to affect the 
activity of the SP-C protein [18]. The fusion is preceded by a His-tag to enable 
its purification through nickel-agarose affinity chromatography. The gels in Fig. 
2 show that the nuclease fusion proteins can be expressed to high levels and 
partially purified on a Ni-agarose resin (Fig. 2A), following which the nuclease 
moiety is removed by specific digestion with thrombin. The two major protein 
bands emerging after cleavage correspond to the nuclease and the rSP-C 
moieties, respectively (Fig. 2B). The lower intensity of the rSP-C (Fig. 2B, lane 3, 
bottom band) compared to the nuclease moiety (top band) results from the six 
times lower molecular weight of the former. Importantly, only less than 10% of 
the total SN/SP-C fusion proteins are expressed as inclusion bodies, as 
estimated from Coomassie-stained gels (not shown). The digestion with 
thrombin yields a variant of SP-C with two additional amino acids at the N-
terminus, namely glycine and proline (rGP/SP-C, Fig. 1, panels B and C). A 
deletion of these two residues rendered a chimera that was still susceptible to 
thrombin digestion, although with a significantly decreased efficiency. The two 
variants were analysed in parallel. During both, the initial purification step and 
the enzymatic cleavage of the nuclease moiety, the presence of detergents is 
essential in order to dissolve the cellular membrane, where a large part of the 
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fusion protein is localised, and, most important, to prevent aggregation of the 
rSP-C. Therefore, to maintain the chimera in an aqueous-detergent 
environment, we optimised the initial purification step and thrombin digestion. 
Experimental parameters investigated included: growth media, concentration of 
inducer (IPTG), size of culture batch, detergent type and concentration, number 
of freeze-thaw cycles and sonication, time and temperature (data not shown). 
The best results were obtained with an initial membrane pelleting, three freeze-
thaw cycles followed by sonication and subsequent addition of the same 
volume of a buffered solution containing 1% lauroyl sarcosine detergent. This 
mixture was centrifuged and the fusion protein was purified from the 
supernatant via immobilized-metal affinity chromatography. Thrombin 
digestion was performed in the presence of the same detergent. 
 
Extraction and purification 
The highly hydrophobic nature of SP-C was used to separate rSP-C from the 
rest of the thrombin reaction mixture. Recombinant SP-Cs are expected to 
partition into the organic phase once the thrombin reaction mixture is subjected 
to organic extraction, whereas the hydrophilic nuclease moiety and thrombin 
would remain in the water-soluble phase. In this way, passing from a detergent-
rich environment to an organic solution, the recombinant protein is likely to 
maintain its helicity, a crucial feature for its activity. Together with the rSP-C 
separation, through the organic extraction procedure we eliminate detergent 
molecules that partition into the organic solvent-water interface. In order to 
study the electrophoretic mobility of the recombinant polypeptides and roughly 
estimate the amount of protein, an SDS-PAGE analysis was performed.  Fig. 2C 
shows aliquots of the organic phase bearing rSP-C (lane 2) and rGP/SP-C (lane 
3) applied to the SDS-PAGE and compared with a known amount of the native 
protein, isolated from porcine lungs (lane 1). In agreement with previous SDS-
PAGE analysis of SP-C [28, 29], native and recombinant peptides run as 
smeared bands with identical electrophoretic mobility, corresponding to an 
apparent molecular weight of ~6 kDa. 
The final purification step involves separation of rSP-C from components 
that could have co-isolated in the organic phase, by using a lipophilic Sephadex 
LH-20 resin. This size exclusion chromatography resin is resistant to organic 
solvents and has been widely used for lipid-lipid and protein–lipid separations 
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[29, 30]. Organic extractions of the natural lung surfactants are subjected to this 
chromatographic procedure in order to separate the lipid fraction from 
surfactant proteins (SP-B and SP-C). Large-scale extractions yielded large 
volumes of extract, therefore a concentration step was necessary to minimise 
the sample volume loaded onto the chromatography column. In order to 
prevent protein self-aggregation and precipitation, we concentrated the rSP-C 
organic-extracted solution, in the presence of egg yolk phosphatidylcholine 
(PC) added at 1:5 protein:lipid ratio (w:w), in a rota-vaporizer. The 
concentrated extract was loaded onto a chloroform:methanol (2:1, v:v)-
equilibrated LH-20 column and eluted using the same solvent system. The 
eluted fractions were measured for their absorbance at 240 and 280 nm (Fig. 
3A). The rSP-C peak was later followed by the presence of a band at the 
expected migration position on SDS-PAGE of the pooled peak fractions (Fig. 
3B). 
The mass spectra of the purified peptides were in agreement with the 
expected molecular masses of 3783 and 3938 Daltons, for rSP-C and rGP/SP-C, 
respectively (Fig 4). The identity of these recombinant surfactant peptides was 
further confirmed by amino acid sequencing (data not shown) and their precise 
concentration was established by amino acid analysis. The final yield obtained 
for purified rSP-C was up to 0.5 mg per litre of bacterial culture. 
  
Secondary structure determination 
In order to test whether the rSP-Cs retained their helical conformation after the 
purification process, their secondary structure was evaluated by circular 
dichroism (CD) spectroscopy (Fig. 5). CD spectra in the far UV region, between 
250 and 190nm, were used to estimate the contributions of different secondary 
structures to the conformation of the proteins. We studied the structure of 
recombinant and native SP-Cs in LPC micelles (Fig. 5A) and lipid (DPPC:POPG, 
7:3 w/w) vesicles (Fig. 5B), to mimic the natural environment of SP-C. As seen 
in Fig. 5, all proteins exhibited CD spectral features consistent with a 
predominantly α-helical conformation, as judged by the presence of two peaks 
at 208 and 222 nm. The spectra of rGP/SP-C and the native SP-C were 
quantitatively comparable and similar to those reported in the literature [29, 
31], while rSP-C exhibited a somewhat higher content of α-helix. To obtain a 
more detailed structural description, the CD spectra were analyzed by using the 
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CDPro suite of programs (SELCON3, CONTIN/LL and CDSSTR) [23, 24]. 
Similar results were obtained with the three programs using a reference set of 
proteins that includes several membrane proteins, which supports the reliability 
of the structure estimation. Table 1 summarises the relative proportions of 
different types of secondary structure obtained, although the values should be 
taken with caution because for small proteins flexibility may reduce the 
dichroic properties of the C=O bond. The increased α-helical content of rSP-C 
relative to the native SP-C is consistent with an N-terminal extension of the 
helical region of the protein, as observed in recent NMR structures of a 
recombinant SP-C mutant and a synthetic SP-C analogue, both bearing 
phenylalanine instead of cysteine residues [26, 32]. Thus, NOE-data supported 
an extended α-helix between residues 11 and 34 in the native protein [12], 
between residues 5 and 34 in the recombinant variant [26], or between residues 
7 and 34 in the synthetic SP-C analogue [32]. 
 
Interfacial adsorption activity 
Figure 6 illustrates the ability of recombinant SP-Cs to promote formation of 
surface-active interfacial films from lipid/protein suspensions, in comparison 
with the activity of native SP-C purified from porcine lungs. We choose the 
mixture of DPPC and POPG in proportion 7:3 (w:w) as a model system because 
it is a simple lipid mixture widely used to mimic roughly the lipid composition 
of LS. Increasing amounts of protein were added to the same amount of lipids 
in order to monitor the protein effect. As shown in Fig. 6, in the absence of 
proteins the lipids hardly adsorbed into the interface. In contrast, in the 
presence of native SP-C, film formation occurs rapidly depending on the 
protein concentration, to reach maximal equilibrium pressures that were 
slightly lower than the expected equilibrium pressure for an interface fully 
saturated with phospholipids during the time assayed. The amount and 
concentration of lipid or lipid/protein material used in these assays was chosen 
to detect potential quantitative differences in the surface activity of the different 
protein preparations. When amounts higher than 10 µg, or concentrations 
higher 1 mg/mL, of phospholipids were used, preparations containing native 
SP-C were able to reach equilibrium surface pressures close to 45-48 mN/m in a 
few minutes (not shown). Under the limiting amounts of material used in the 
present adsorption experiments, rSP-C and rGP/SP-C exhibited slightly, but 
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consistently, better activity, with the mixtures containing the highest amount of 
protein reaching equilibrium pressures of 48 mN/m in a few minutes. This 
suggests an optimal interaction of the recombinant peptides with the 
phospholipids. Optimal adsorption activities have been previously reported for 
other rSP-C forms expressed in bacteria using different strategies [15, 33, 34], 
but a quantitative comparison of their activity with respect to native SP-C under 
limiting conditions was not been performed. 
 
Compression isotherms 
To get a deeper insight into the apparently higher surface activity of the 
recombinant forms of SP-C produced here, we have analyzed in detail the π-A 
compression isotherms of DPPC/dipalmitoyl-phosphatidylglycerol (DPPG) (7:3, 
w/w) films in the absence and in the presence of different proportions of the 
native porcine SP-C or the recombinant rSP-C or rGP/SP-C forms. For these 
experiments we have used only disaturated lipids to preserve the main features 
of the isotherm, including the conspicuous liquid-expanded (LE)-to-liquid-
condensed (LC) transition plateau, which occurs at around 10 mN/m in either 
DPPC or DPPG films at 25°C. Figure 7 shows that progressive proportions of 
the three proteins induce a shift of the isotherms towards increasing molecular 
area, as a result of the space taken by the protein molecules. Overall, 
recombinant proteins produce larger expansions of the isotherm than the native 
palmitoylated protein. This observation indicates that the structural changes 
introduced at the N-terminal segment of the recombinant forms with respect to 
native SP-C have significant consequences on the disposition and/or orientation 
of the protein at the interface. Lipid-protein films containing the three analyzed 
proteins produce isotherms that converge upon compression with the isotherms 
of the pure lipid monolayers at similar pressures of around 50 mN/m. This 
feature is consistent with a similar stability of the three proteins at the interface, 
from where they are squeezed-out at similar compression states. It is 
remarkable that the compression-driven exclusion of the three proteins is 
accompanied by the squeeze-out of some lipid molecules, as deduced from the 
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progressive shift of the isotherm to smaller areas at pressures higher than 50 
mN/m [35]. The extent of such a shift increases progressively with the amount 
of protein present. Again, the recombinant SP-C forms produce larger shifts of 
the isotherms than native SP-C when lipid-protein films are compressed 
beyond 50 mN/m. In Figure 8 we have plotted the percentage of area removed 
from the interface in lipid/protein films compressed to 60 mN/m –a pressure 
well above the squeeze-out plateau of the isotherms- with respect to the area 
occupied by a pure lipid film at the same pressure, as a function of the molar 
proportion of protein in the films. Assuming that all protein molecules were 
squeezed-out from the interface upon compression up to 60 mN/m, the slope of 
these plots gives an estimate of the molar lipid/protein ratio excluded. In this 
case, each native SP-C molecule could be squeezed-out accompanied by 17±2 
lipid molecules, while rGP/SP-C and rSP-C expel 25±2 and 53±3 phospholipids 
per protein molecule, respectively. Previous calculations had already suggested 
that the squeeze-out of native SP-C from compressed DPPC/DPPG films is 
accompanied by around 10 molecules of phospholipid per mol of protein [35]. 
Analysis by electron spin resonance of the stoichiometry of the interaction of 
SP-C with phospholipids in bilayers allows estimating that around 18 
phospholipid molecules interacted with each SP-C molecule at saturation [36]. 
Although the numbers obtained from our isotherms may not be entirely correct 
without considering the protein segments that could still be inserted into the 
films at high pressures, the differences observed clearly indicate that the 
recombinant proteins bearing phenylalanines remove more lipid molecules per 
mol of protein than the native acylated protein. This feature can be correlated 
with a potentially higher affinity of the N-terminal segment of the recombinant 
proteins to maintain association with phospholipids, compared with the natural 
SP-C, which could be also responsible for the observed higher ability to 




The production of a recombinant SP-C has been a challenging task since the 
revealing of its importance in the late 80s. The extreme hydrophobicity and its 
tendency to aggregate make this protein very difficult to manipulate and many 
different approaches have been taken in order to circumvent these features. 
Synthetic peptides [12, 28, 37] and peptoids [38] mimicking the essential 
structural features of SP-C have been tested to enhance the surface-active 
properties of surfactant formulations composed of synthetic phospholipids, 
being in all cases less effective than the native (animal-extracted) SP-C. 
Concerning the recombinant expression of the protein, efforts have been made 
both for a eukaryotic baculovirus expression system [39] and using bacterial 
cultures [15, 33]. We decided to employ a prokaryotic system in order to obtain 
SP-C in large quantities, since bacteria are to date the best large-scale protein-
producing organism. Compared to the previously published rSP-C expressed in 
Escherichia coli as a fusion to the N-terminal portion of bacterial 
chloramphenicol acetyl transferase, our strategy results more protective of the 
α-helical conformation necessary for optimal surface activity. This is probably 
because our method does not involve resolubilisation of the protein from 
inclusion bodies and exposure to polar solvents during RP-HPLC [15]. In 
addition, the use of the nuclease A (SN) as a fusion partner provides several 
advantages (reviewed in [40]) for high-level heterologous expression of integral 
membrane proteins at full-length. For instance, the three-dimensional structure 
of SN shows numerous basic residues exposed to the solvent [41], therefore 
precluding aggregation of fusion proteins and becoming a versatile system for 
membrane protein over-expression. 
We expressed a modified sequence of human SP-C, which bears two 
phenylalanines instead of palmitoylated cysteines, inspired by the native 
sequence of SP-C from dog and mink surfactants. The role of palmitoyl chains 
in SP-C is still under debate. It is evident that SP-C maintains its function in the 
presence of one phenylalanine instead of a palmitic chain, as in the case of dog 
and mink SP-Cs, and the possibility remains that this particular amino acid can 
mimic at least partially the role of palmitic chains. The fact that this mutant 
variant has been successfully used both in vitro and in animal experiments 
supports the idea that it could be a functional equivalent to the natural SP-C 
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[18].  Our interfacial adsorption measurements together with compression 
isotherms suggest that, at least for the bilayer-monolayer conversions, these 
modified SP-C versions could have superior properties than the native SP-C 
purified from animal lungs. The compression isotherms of phospholipid films 
containing increasing proportions of protein indicate that the recombinant 
versions of SP-C expel more phospholipid molecules from the interface than the 
native SP-C, when the lipid-peptide films are compressed beyond the collapse 
pressure of the protein. These results suggest that the aromatic residues 
included into the N-terminal region of the recombinant forms may either 
increase the affinity of the protein to associate with phospholipids or promote a 
more appropriate conformation of this region to accommodate a higher number 
of lipid molecules. Additionally, our production procedure, which maintains 
the structural integrity of the recombinant SP-C forms, may preserve better its 
activity in quantitative terms, compared to the delipidation and purification 
procedure of native SP-C from animal lungs. The role of SP-C in vivo has been 
mostly discussed in connection to the protein-mediated stability of the 
interfacial surface active film at end-expiration, and not much as promoting 
interfacial adsorption, an activity which is better performed by SP-B [1]. 
However, there are strong indications suggesting that a Phe-containing rSP-C 
version has enough surface activity to be used as the only protein component of 
a therapeutic surfactant preparation [15, 17]. The N-terminal segment of SP-C 
has been revealed as a very dynamic structural motif [42], which is able to 
interact and perturb the phospholipid packing of phospholipid bilayers and 
monolayers [43]. Acylation of this segment may be especially important to 
maintain association of the lipid/protein structures squeezed-out from the 
compressed films at end-expiration with the interface [44]. In native surfactant 
complexes, efficient bilayer-monolayer (during adsorption) and monolayer-
bilayer (during compression) conversions are ensured by the presence of SP-B. 
A high affinity of the protein to associate with the interface has been recently 
shown to be a crucial determinant for the SP-B activity, this association being 
critically dependent on the presence of aromatic residues at the N-terminal 
segment of the protein [45]. It is thus reasonable to expect that in the absence of 
SP-B, SP-C variants with enhanced affinity for the interface may show enough 
activity to promote bilayer-monolayer transitions and serve as the only additive 
needed for efficient therapeutic surfactant formulations. Further biophysical 
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studies of the surface behaviour of these and other variants are ongoing and 
will allow the establishment of their potential as SP-C (or SP-B) mimics, as well 
as the determination of critical structure-function motifs.  
The protocol presented here is a combination of a common strategy for 
over-expression of integral membrane proteins and the organic extraction used 
for native SP-C isolation from animal pulmonary lavages. This purification 
scheme may also be used for obtaining other highly hydrophobic proteins. The 
flexibility for creating mutants of the SP-C, aiming to specific structural or 
functional studies, will greatly improve our understanding of the role of this 
protein in the LS, as well as optimizing current replacement preparations for 
respiratory diseases. Further biophysical studies are in progress in order to 
explore the full potential of these and new SP-C variants for surfactant therapy. 
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FIGURE LEGENDS 
Figure 1. Comparison between sequences of SP- C from different origins and 
sequence and schematic organisation of the rSP-C variants. (A) Native SP-C 
sequence alignment highlighting the Cys residues in blue and Phe residues in 
red. In the porcine sequence the helical region from the NMR structure [46] is 
boxed. (B) Amino acid sequences of the rSP-Cs produced in this work. (C) 
Schematic organisation of the chimerical protein expressed in bacteria. 
Figure 2. SDS-PAGE analyses of over-expressed chimeric proteins, thrombin 
digestion and organically extracted native and rSP-C. (A) Representative 
Coomassie blue-stained 12% SDS-PAGE of aliquots taken during the 
purification of chimeric proteins. Lane 1, molecular markers; lane 2, whole cell 
extract; lane 3, supernatant of bacterial lysate; lane 4, nickel column flow 
through; lane 5, eluate form nickel column. The SN/SP-C chimera is marked 
with an arrowhead to the right. (B) Coomassie blue-stained 15% acrylamide 
tricine gel loaded with an aliquot of the SN/SP-C chimera after (lane 2) and 
before thrombin digestion (lane 3). (C) Native (lane 1) and rSP-Cs (rGP/SP-C, 
lane 2 and rSP-C, lane 3) organically extracted were resolved on a 16% 
acrylamide SDS-PAGE stained with Coomassie blue. 
Figure 3. Purification of rSP-Cs by Sephadex LH20. (A) LH 20 
chromatographic analysis of organic extracts. Absorbance at 240 (black line) and 
280 (grey line) nm was monitored. (B) Comassie blue stained SDS-PAGE 
analysis of increasing aliquots of the initial peak (lanes 1- 3) and two aliquots of 
the distal peak (lanes 4 and 5). Lane 6 was loaded with 15 µg of native SP-C. 
Size markers are indicated on the left. 
Figure 4. Mass spectra of rSP-Cs purified on Sephadex LH20. 
The content of the first peak in the chromatograms of Figure 3 were analysed by 
MALDI-TOF-MS as described in Materials and Methods. rGP/SP-C and rSP-C 
spectra are shown in panels A and B, respectively. 
Figure 5. Circular dichroism spectra of native and recombinant SP-Cs 
reconstituted in surfactant-mimetic media. Native SP-C (solid line), rGP/SP-C 
(dotted line) and rSP-C (dashed line) spectra were recorded in the presence of 
LPC micelles (panel A) and DPPC:POPG  (7:3) vesicles (panel B). In all samples 
25 µM of proteins were analysed (see Materials and Methods). 
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Figure 6. Interfacial adsorption activity. The panels show the π-t adsorption 
isotherms for interfacial film formation after deposition of 10 µL of 10 mg/mL 
DPPC:POPG (7:3) suspension in the absence or presence of 2, 5 or 10% native 
SP-C (panel A), rGP/SP-C (panel B) or rSP-C (panel C).  
Figure 7. Compression π-A isotherms of lipid and lipid/protein films. Films 
of DPPC/DPPG (7:3, w/w) in the absence (bold lines) or presence of 2% 
(circles), 5% (triangles) or 10% (squares) of the SP-C variants were formed by 
spreading lipid or lipid-protein mixtures in chloroform/methanol 3:1 (Volvo) 
on top of a buffered sub-phase Tris 5mM pH 7, containing 150 mM NaCl. The 
compression rate was 65 cm²/min and the temperature was 25ºC. 
Figure 8. Effect of native and recombinant forms of SP-C on the removal of 
lipid/protein material from highly compressed interfacial films. Percent of 
DPPC/DPPG film area at 60 mN/m reduced by the presence of native porcine 
SP-C (closed circles), rGP/SP-C (open circles) or rSP-C (open squares), has been 
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